Find an expert

Professor Pettit leads the Bones and Immunology Research Group at Mater Research Institute-UQ and is Director of Biomedical Research for Mater Research. Professor Pettit has led multidisciplinary research discovering intersecting biological mechanisms across the fields of immunology, rheumatology, cancer biology, haematology and bone biology. Professor Pettit is currently a UQ Amplify recipient associated with an ARC Future Fellowship, 2017-2020 and CIA on an NHMRC Ideas Grant, 2022-25. Major contributions led by Professor Pettit include the paradigm shifting discovery of a novel population of resident macrophages, osteal macrophages (osteomacs), and their role in promoting bone formation and bone regeneration after injury. Her team have published over 17 manuscripts based on this original discovery (with over 1700 citations) including translation of this basic research discovery toward eluciating novel disease mechanism from cancer bone metastasis to osteoporosis. This also led to the novel discovery of bone marrow resident macrophage contributions to supporting blood stem cells niches and the key role that these cells play in protecting this vital niche from cancer therapies. Bone marrow and specifically haematopoietic stem cell damage is one of the most serious and life-threatening side effects of cancer therapies. Here discoveries are cited in over 117 patent documents and she is currently collaborating with a major pharmaceutical partner.

Professor Pettit's leadership and achievements have been recognised through multiple awards including the 2019 UQ Faculty of Medicine Leader of the Year (Academic), Women in Technology 2018 Life Sciences Outstanding Achievement Award and becoming a Fellow of the American Society of Bone and Mineral Research. Professor Pettit has been invited to give numerous presentations at national and international conferences including Seoul Symposium on Bone Health, Asia-Pacific League of Associations for Rheumatology Congress and a prestigious American Society of Bone and Mineral Research Meet-the-Professor session. Professor Pettit is and Associate Editor for the Journal of Bone and Mineral Research, is an past Council member for the Australian and New Zealand Bone and Mineral Society, and chairs or serves on numerous committees including the Association of Australian Medical Research Institutes Gender Equity, Diversity and Inclusion Committee. PhD candidates under Professor Pettit's supervision have all been supported by scholarships (including 2 x NHMRC), received numerous local and national awards (e.g. Dr Alexander, ASMR QLD Premier Postgraduate Award, 2011 and Dr Lena Batoon won the UQ Faculty of Medicine Graduate of the Year Award, 2021), all had high quality first author publications at completion and 2 received UQ Dean’s Commendations.

Profile Summary

Dr Sandro Porceddu is an internationally recognised radiation oncologist and a leading authority in head and neck and skin cancer. With over 20 years experience in medicine his areas of clinical expertise include head and neck cancer, skin cancer, sarcoma and lymphoma. He is currently a senior radiation oncologist and Director of radiation oncology research at the Princess Alexandra Hospital, Brisbane, Professor of Medicine, University of Queensland and Associate Editor for the International Head and Neck journal, Oral Oncology.

Dr Porceddu is a nationally and internationally recognised cancer advocate through his involvement in high-level committees, engagement with key policymakers, community education and media roles.

Career Summary

Professor Porceddu completed his medical degree at Monash University before undertaking his residency at Monash Medical Centre, Melbourne. He commenced his specialist training in radiation oncology at the Peter MacCallum Cancer Centre in 1996 and was made Fellow of the Royal Australian and New Zealand College of Radiologists, Faculty of Radiation Oncology in 2000. After working as a consultant radiation oncologist at PeterMac for several years he moved to the Princess Alexandra Hospital in 2004.

Professional Committees and Organisations

Professor Porceddu has been the President of the Clinical Oncology Society of Australia (COSA), the peak organisation for cancer-related health professionals, and the Trans Tasman Radiation Oncology Group (TROG), one of the largest cancer collaborative trials group in Australia/New Zealand. He has served on numerous national and international professional and academic committees including the board of the Cancer Council of Australia, the National Cancer Expert Reference Group for the Commonwealth and the International Union for the Control of Cancer (UICC) TNM Expert Advisory Panel.

Currently, he is the Chair of the Cancer Council Queensland Co-operative Oncology Group, a committee that provides over $1.2M per annum to support clinical research throughout Queensland and is on the board of the of the Head and Neck Cancer InterGroup (HNCIG), a group of leading world cancer experts dedicated to promoting the global harmonisation of head and neck cancer research and treatment.

Academic Highlights

Professor Porceddu runs an active clinical research program with over 150 peer-review articles, book chapters, published abstracts, invited reviews and commentaries. He has received invitations to speak at major international conferences such as the American Society of Clinical Oncology (ASCO) meeting and publish in prestigious journals such as the Lancet Oncology and Journal of Clinical Oncology.

Awards

Trans Tasman Radiation Oncology Group Outstanding Contribution

American Head and Neck Society Chris O’Brien Travelling Scholar

Pre-eminent status by Queensland Health

Rouse Fellowship, Royal Australian and New Zealand College of Radiologists

Teaching

Dr Porceddu has had a life-long commitment to teaching and is a supervisor and mentor to Doctor of Philosophy and Master of Philosophy candidates, Clinical Research Fellows, MBBS Honours students, resident, registrars and other allied health professionals.

NAME Professor Elizabeth Ellen POWELL

POSITION TITLE Professor, School of Medicine, The University of Queensland; Hepatologist, Princess Alexandra Hospital

Email e.powell@uq.edu.au

EDUCATION/TRAINING

Bachelor of Medicine and Bachelor of Surgery with First Class Honours (M.B.,B.S.Hons1), The University of Queensland

Fellow of the Royal Australasian College of Physicians

Doctor of Philosophy (PhD), The University of Queensland

Fellow of the Royal College of Physicians, London

Fellow, American Association for the Study of Liver Diseases

Elizabeth Powell is a Hepatologist and Senior Staff Specialist in the Department of Gastroenterology and Hepatology, Princess Alexandra Hospital. She is also Professor, School of Medicine, The University of Queensland, Director of the network Centre for Liver Disease Research in The University of Queensland and a Research Fellow with the American Association for the Study of Liver Diseases. She is also a recent past member of the Executive of the Australian Liver Association.

Professor Powell has a very productive research group, bridging basic science and clinical research. Her main research interests include:

(i) developing strategies to improve the assessment of non-alcoholic fatty liver disease by primary care clinicians and non-hepatology specialists.

(ii) examining ways to improve education and medication management for people with decompensated cirrhosis (advanced liver disease)

(iii) examining the role of injury-stratifying biomarkers for non-alcoholic fatty liver disease

I am a Principal Investigator (PI) and a senior research officer (SRO) at Mater research – UQ with excellent clinical and research laboratory skills and expertise in conducting and analyzing laboratory assays and resolving complex research and clinical laboratory problems. I can describe myself as determined, reliable, studious, conscientious, attentive, industrious, diligent, and focused on the timely, quality completion of all lab procedures. I am able to work well under pressure and time constraints within high-volume environments both independently and in collaboration within a team. I am also a highly self-motivated and career-oriented individual with a genuine interest in addressing cancer molecular mechanisms with the goal of developing novel cancer therapeutics and immunotherapy focusing on tumor microenvironment, immunoregulation and signaling pathways in cancer and metastasis.

Professor Reade is Director of the Greater Brisbane Clinical School and Professor of Military Medicine and Surgery at UQ. The Greater Brisbane Clinical School comprises all the Brisbane teaching hospitals of the University of Queensland along with the preclinical teaching resources of the St Lucia campus and the General Practice Clinical Unit. A specialist intensive care physician, anaesthetist and clinician-researcher, he also leads a program of research relevant to military trauma medicine and surgery that holds equal promise for severely injured civilian trauma patients.

After clinical training in anaesthetics and intensive care medicine in Sydney, Melbourne, Oxford and Pittsburgh, a doctorate in the molecular pathogenesis of nitric oxide production in human septic shock from the University of Oxford and a postdoctoral research fellowship in clinical trials and epidemiology from the University of Pittsburgh, Michael returned to Australia as Associate Professor of Intensive Care Medicine at the Austin Hospital & the University of Melbourne in 2007. Michael held faculty appointments at the University of Oxford (where he taught physiology), the University of Pittsburgh (where he was an Instructor in critical care), and currently holds adjunct or honorary appointments at the University of London, the US Uniformed Services University of the Health Sciences, the University of Melbourne and Monash University. He has supervised postgraduate students in basic, applied and clinical research, and is a Fellow of the Higher Education Academy of the United Kingdom.

In parallel with his academic and clinical work, Michael served in the Australian Army Reserve until his appointment to the full-time ADF Chair in 2011. He was commissioned as a General Service Officer in the Australian Army in 1990, and prior to his appointment to UQ had deployed to Bosnia and Kosovo (on attachment to the British Airborne Brigade), Timor, the Solomon Islands and Afghanistan. In 2013 he commanded the Australian Specialist Health Group at the NATO ISAF Role 3 Hospital in Kandahar, Afghanistan, and in 2015 in Iraq he was the first Director of Clinical Services of the ADF hospital deployed in support of Operation Inherent Resolve. He deployed again to Iraq in 2016 and 2017. From 2015-2018 he was the Director of Clinical Services of the Australian Regular Army's only field hospital. In 2017 he led this unit to become the first ever ADF hospital accredited by the Royal Australasian College of Surgeons Trauma Verification Program. He was recognised for this service by appointment as a Member in the Military Division of the Order of Australia in the 2019 Queen's Birthday Honours List. From 2019-2022 on promotion to Brigadier he was appointed Director General Health Reserve - Army, responsible for technical regulation of specialist medical, nursing and allied health support. He remains a senior clinical advisor to Joint Health Command of the Australian Defence Force.

Professor Reade's clinical research focusses on treatments for exsanguinating haemorrhage, improving trauma systems, and preventing and treating acute cognitive impairment (such as that which results from traumatic brain injury). He is the Chief Investigator in an NHMRC-funded clinical trial of cyropreserved (frozen) platelets, a technology which holds equal promise to military and civilian trauma patients, particularly those in smaller hospitals. He is also a Chief Investigator in NHMRC-funded multicentre clinical trials of tranexamic acid and fibrinogen concentrate (drugs thought to reduce mortality from traumatic bleeding), the effect of erythropoietin on inflammation and mortality after severe trauma, a novel anti-delirium strategy for use in critically ill patients, and an advanced MRI/biomarker study in traumatic brain injury. He has active research collaborations with Australian Red Cross Lifeblood, the National Trauma Research Institute, the Australian and New Zealand Intensive Care Research Centre at Monash University, the ANZICS Clinical Trials Group and the ANZCA Clinical Trials Network.

Professor Reade is also developing a research programme focussed on trauma systems design, in collaboration with colleagues at the Jamieson Trauma Institute on the Royal Brisbane and Women's Hospital campus, Australian state ambulance services and the US and UK armed forces, aiming (for example) to optimise the allocation of prehospital and hospital resources in the management of life-threatening trauma.

Professor Reade currently supervises 10 postgraduate students (including 4 PhD students) and one postdoctoral research fellow, most of whom are Defence Force officers. He holds or has held research grants totalling >A$51M, has published >230 peer-reviewed papers and delivered >440 lectures at national and international conferences. From 2019-2021, Professor Reade was President of the Australasian Trauma Society.

Associate Prof Amy McCart Reed holds a PhD in molecular biology from The University of Queensland. She is a Fellow of the Faculty of Science of the Royal College of Pathologists Australasia. Her early postdoctoral work focused on understanding the genetic basis of colorectal cancer using experimental disease models, as part of a Cancer Research UK-funded colorectal cancer program led by Professors Ian Tomlinson and Andrew Silver. After returning to Australia, she was recruited to the Molecular Breast Pathology group at UQ’s Centre for Clinical Research and has undertaken a series of studies investigating the genomic landscape of breast cancer special types. Amy's research program includes studies on Metaplastic breast cancer and Invasive Lobular Carcinoma, two breast cancer special types in need of targetted therapy options. A/Prof McCart Reed is the scientific lead on an MRFF-funded genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, 'Q-IMPROvE'. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.

Dr Sarah Reedman is a Postdoctoral Research Fellow at the Queensland Cerebral Palsy and Rehabilitation Research Centre group within the UQ Child Health Research Centre. Sarah is passionate about enabling participation of young people with disabilities in sports and active recreation. She is interested demonstrating how paediatric physiotherapists, occupational therapists and exercise physiologists are well-placed to deliver effective physical activity promotion interventions in young people with disabilites. Sarah is also involved in the conduct of a large, multi-site randomized controlled trial of an intensive functional goal-directed motor training intervention in children with bilateral cerebral palsy (Hand Arm Bimanual Intensive Training Including Lower Extremity [HABIT-ILE]).

Sarah is experienced in the following research methods:

• Design, conduct and administration of randomized controlled trials (including multi-site trials)
• Cross-sectional and cohort studies
• Validation of rehabilitation outcome measures
• Objective measurement of physical activity behaviours, tri-axial accelerometry

Sarah is available as an associate supervisor for HDR students.

Matthew J. Roberts, BSc, MBBS, PhD, FRACS (Urol)

• Consultant Urologist, Royal Brisbane and Women’s (RBWH), Surgical Treatment and Rehabilitation Service (STARS), Queensland Health
• Clinician Research Fellow, Metro North Hospital and Health Service
• Group Leader & Associate Professor, The University of Queensland Centre for Clinical Research

Matthew is a medical graduate of The University of Queensland and completed Urology specialty training in Queensland and New South Wales. He completed his PhD under the supervision of Professor “Frank” Gardiner investigating new biomarkers for the early detection and characterization of prostate cancer.

Matthew is a surgeon-scientist, working clinically as a urologist and robotic surgeon at RBWH & STARS with academic appointment as Clinician Research Fellow at Metro North Health (Qld) and Associate Professor at UQCCR. His clinical and research interests are in Urologic cancers (e.g. prostate cancer), focusing on novel imaging and biomarkers, clinical trials, urological infections and innovation in urology. He has authored over 140 peer reviewed manuscripts in international journals and presented research at more than 20 international urology and clinical cancer meetings. He is a member of the EAU Prostate Cancer Guidelines Committee, Prostate Cancer Outcomes Registry (PCOR)-Queensland Steering Committee, Editorial Board of the BJU International, as well as Co-Convenor of the ANZUP 2024 ASM.

Michael (Mike) Roberts is a NHMRC Senior Principal Research Fellow and Emeritus Professor of Clinical Pharmacology & Therapeutics and Director of the Therapeutics Research Centre in the Diamantina Institute at The University of Queensland, which is based in the Translational Research Institute adjacent to the Princess Alexandra Hospital in Brisbane, Qld, Australia. He is also Professor of Therapeutics & Pharmaceutical Science at the University of South Australia with laboratories in the Basil Hetzel Institute at The Queen Elizabeth Hospital in Adelaide, South Australia.

Professor Jason Roberts is Director of the University of Queensland Centre for Clinical Research (UQCCR), an Australian National Health and Medical Research Council (NHMRC) Leadership Fellow L2 at The University of Queensland. He is also a Consultant Clinical Pharmacist at the Royal Brisbane and Women’s Hospital and Interim Director of the Herston Infectious Diseases Institute (HeIDI). He is Director of the NHMRC-funded Centre for Research Excellence RESPOND which is based at UQCCR. He is a clinician-scientist with a strong interest in research and his principal research theme is optimization of antimicrobial dosing in the critically ill. Prof Roberts has authored over 650 published papers and book chapters on this topic, has been awarded over $55 million in grants and has supervised >20 PhD students to completion.

Prof Roberts was recognised as Australia’s leading researcher in two separate categories, Critical Care and Communicable Diseases, by the Australian’s 2019 Research Magazine.

He has been invited to present his results at major international conferences in critical care, infectious diseases, pharmacy, nephrology, transplant and safety. He has served on the Critical Review Panel for ATS/IDSA Guidelines of HAP, HCAP and VAP and the Australian Therapeutic Guidelines - Antibiotic and the 2021 Surviving Sepsis Guidelines. He is the Past Chair of the Working Group for Antimicrobial Use in ICU for the European Society of Intensive Care Medicine and an Executive Member of the PK/PD Group (EPASG) within the European Society for Clinical Microbiology and Infectious Diseases (ESCMID).

He is Section Editor for the International Journal of Antimicrobial Agents and an Associate Editor of the Journal or Pharmacy Practice and Research, the journal for the Society of Hospital Pharmacists of Australia and an Associate Editor for Pharmacotherapy and Aanesthesiology Pain and Critical Care Medicine journal. He has convened >50 seminars/conferences including being co-convenor for Medicines Management 2013, The National Conference for Society of Hospital Pharmacists of Australia.

He also engages with Industry to perform studies that develop optimised antibiotic dosing regimens that maximise antibiotic efficacy for testing in clinical trials or for use in special patient populations (e.g. critically ill, pneumonia, dialysis).

Prof Katharina Ronacher obtained an MSc degree in Medical Biochemistry from the University of Vienna (Austria). Thereafter, she was awarded a prestigious fellowship from the Austrian Ministry of Science and Technology to complete a PhD at the University of Cape Town (South Africa). She completed her post-doctoral fellowship at Stellenbosch University, where she was subsequently offered a faculty position. Prof Ronacher was Senior Scientist on several large clinical research trials funded by the Bill and Melinda Gates Foundation, the European Union and the US National Institutes of Health with focus on identification of biomarkers for tuberculosis (TB) treatment response. In parallel, she established her independent research group investigating how endocrine factors impact immune responses to TB, for which she received uninterrupted funding from national and international funding bodies since 2008. In 2015, she was awarded a NIH R01 grant for her ground-breaking research into the underlying immunological and metabolic mechanisms of increased susceptibility of diabetes patients to TB. With this grant she has lead the international ALERT Consortium with clinical field sites in South Africa and at the Texas/Mexico border.

She relocated to Brisbane in 2017, where she now heads the Infection, Immunity and Metabolism group at the Mater Research Institute – University of Queensland, but continues to collaborate with clinicians and researchers in South Africa, the USA and Europe and holds an affiliate appointment as Professor Extraordinary at Stellenbosch University.

Prof Ronacher's current research investigates the underlying immunological mechanisms contributing to more severe bacterial and viral respiratory infections in obesity and diabetes. Her research provides critical insights into the role of cholesterol and its derivatives in regulation of inflammation in the lung and how this knowledge can be exploided for novel therapeutic approaches to treat respiratory infections.

Tanya is a certified practising speech-language pathologist who has a particular clinical and research interest in both paediatric and adult language. She has experience in conducting mixed-methods studies.

Tanya’s research interests include exploring family-centred models of care and client outcomes using the International Classification of Functioning, Disability and Health framework when working with young children who are ‘late talkers’ or who have a developmental language delay/disorder and their families.

Tanya is also passionate about the provision of accessible health information to adults who have aphasia post-stroke and to their family members. Tanya undertook her doctoral research within the Communication Disability Centre (CDC) at The University of Queensland. She is particularly interested in patient education and ensuring people with aphasia, their family, and friends receive appropriate health information and access to services across the continuum of care.

Dr Megan Ross (she/her) is a titled research physiotherapist and postdoctoral research fellow at RECOVER Injury Research Centre, The University of Queensland. She is part of a research team, led by Professor Trevor Russell, which focuses on developing more effective and efficient health services supported by technology innovation. Megan’s current research projects include exploring consumer perspectives of the telerehabilitation service delivery model, factors that influence the uptake and utilisation of telerehabilitation, and exploring the acceptability and usability of digital health innovations. Megan has a broad range of research skills that span both quantitative and qualitative methods and co-design approaches, including systematic reviews, cross-sectional and longitudinal study designs and data analysis, discrete choice experiments, interviews and focus group discussions and thematic analysis.

Dr Ross received a Bachelor of Physiotherapy (with First Class Honours) in 2012 and a PhD in Physiotherapy in 2020 from The University of Queensland. Megan is the inaugural Chair of the Australian Physiotherapy Association’s LGBTQIA+ Advisory Committee, is Deputy Chair of the Australian Physiotherapy Associations’ National Advisory Committee and sits on the Queensland Gender Affirming Network Steering Committee. Dr Ross leads a program of research in the area of LGBTQIA+ experiences of, and access to healthcare with a focus on physiotherapy and allied health. Megan is passionate about ensuring safe and affirming access to healthcare for people with diverse gender identities, sexual orientations and sex characteristics and has received over $1M AUD in funding, including a CIA MRFF grant to co-design, implement and evaluate an LGBTQIA+ affirming model of primary care. The overarching objective of Dr Ross’s work is to improve access to, provision of, and experiences with health care and ultimately contribute to improved health and wellbeing for the LGBTQIA+ communities.

I currently have a number of research interests, both in Biomedical and well as in Teaching-Focussed Research.

Biomedical projects have traditionally been done with collaborators, and some of the projects have included:

• mechanisms of action of animal venoms and toxins, and we have used the organ bath laboratory and pharmacologoical techniques as bioassays
• study of bitter tasting compounds on pig digestive processes, to better understand activation of bitter taste receptors in vivo

Teaching-focussed interested are around university student behaviour with regard to learning activities and engagement. Universities around the world are grappling with shifts in effective and engaging educational strategies, as well as student expectations, in their delivery of content. In an age where students can do on-line courses at universities far from Australia, academics are carefully considering student engagement and success here at UQ.

• Lecture slots currently have the bulk of contact hours in most courses, with ~39 lectures per course across a semester. These are largely recorded and used as a teaching resource. Student attendance to the traditional lecture spaces has decreased significantly across all campuses, with a UQ average of ~60% across all courses. This type of analysis has recently led to UQ offering smaller venues for larger courses in which there have been patterns of partial attendance.
• My work seeks to better understand what motivates students to attend these spaces in their traditional sense and in the transition to an increasing number of flipped classroom models and blended learning, where the academics are less on the stage, and are instead facilitating activities for learning, while students will be engaged in learning content largely outside the lecture slots.
• "Embracing the Unknown" Experience in third year science courses is also an interest, in which research work and its associated uncertainties cause varying levels of anxiety in some students. Best understanding this process and supporting students through it is also an interest of mine.

Trevor Russell is a Professor of Physiotherapy and the Director of the RECOVER Injury Research Centre where he leads a stream of research on Technology Enabled Rehabilitation. He is also co-director of both the Centre for Research in Telerehabilitation and the Telerehabilitation Clinic at the University of Queensland. His research focusses on the use of digital technologies for the remote delivery of health services with a particular focus on telerehabilitation technologies. Specifically his research aims to develop innovative computer based hardware and software solutions to enable the provision of rehabilitation services remotely via the Internet; to further the evidence base of technology enabled rehabilitation through controlled clinical trials; to evaluate the treatment efficacy of specific technology enabled interventions; investigate cost-benefit factors related to technology enabled services; and develop best practice guidelines for the implementation of technology enabled services in the rehabilitation sciences. His work is amongst the earliest and most extensive in this field.